Literature DB >> 7336137

Clinical and subclinical hepatitis A occurring after immunoglobulin prophylaxis among Swedish UN soldiers in Sinai.

O Weiland, B Niklasson, R Berg, P Lundbergh, L Tideström.   

Abstract

This study was performed to investigate the efficiency of 5 ml of 16.5% immunoglobulin (Ig) with an antibody titer against hepatitis A (anti-HAV) of 1:4000, using the HAVAB RIA technique, as pre-infection prophylaxis in 610 Swedish UN soldiers stationed in Sinai for 6 months. Sera were collected from 553 of these soldiers before, during, and after their service and were tested by the HAVAB technique for anti-HAV. Only 13 of 553 (2.4%) were immune before their service. During the first 5 months in Sinai, only one subclinical case of hepatitis A occurred among the men. Thereafter, two subclinical and four clinical cases occurred, although one of the subclinical cases and the four clinical ones did not occur until after the 6-month period. Thus, the Ig prophylaxis scheme used seems to offer almost complete passive protection for 5 months.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7336137     DOI: 10.3109/00365528109181012

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  4 in total

Review 1.  Innate and adaptive immune responses against picornaviruses and their counteractions: An overview.

Authors:  Andreas Dotzauer; Leena Kraemer
Journal:  World J Virol       Date:  2012-06-12

Review 2.  New hepatitis A vaccines and their role in prevention.

Authors:  D B Strader; L B Seeff
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

3.  Acute viral hepatitis A, B and non-A, non-B in Stockholm in the 1950s and 1970s: a comparison.

Authors:  O Weiland; J V Berg; B Bjorvatn; B Flehmig; P Lundbergh
Journal:  Infection       Date:  1981       Impact factor: 3.553

4.  Serological hepatitis A virus infections and ratio of clinical to serological infections in a controlled trial of pre-exposure prophylaxis with immune serum globulin.

Authors:  J D Kark; S Bar-Shany; S Shor; L Merlinski; E Nili
Journal:  J Epidemiol Community Health       Date:  1985-06       Impact factor: 3.710

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.